Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 514.07 -0.38% -1.96
REGN closed down 0.38 percent on Tuesday, December 1, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical REGN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.38%
Stochastic Buy Signal Bullish -0.38%
Pocket Pivot Bullish Swing Setup -0.38%
Outside Day Range Expansion -0.38%
Up 3 Days in a Row Strength -0.38%
Oversold Stochastic Weakness -0.38%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 1.13%
Older End-of-Day Signals for REGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
Up 1% about 17 hours ago
Rose Above Previous Day's High about 18 hours ago
Rose Above 10 DMA about 18 hours ago
10 DMA Support about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Biotechnology Biopharmaceutical Health Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Macular Edema Atopic Dermatitis Sanofi Breakthrough Therapy Metastatic Colorectal Cancer Allergic Asthma Immune Diseases Muscle Diseases Regeneron

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 664.64
52 Week Low 328.12
Average Volume 991,085
200-Day Moving Average 562.34
50-Day Moving Average 564.31
20-Day Moving Average 543.05
10-Day Moving Average 517.28
Average True Range 16.74
ADX 23.4
+DI 18.66
-DI 28.20
Chandelier Exit (Long, 3 ATRs ) 546.59
Chandelier Exit (Short, 3 ATRs ) 556.01
Upper Bollinger Band 598.34
Lower Bollinger Band 487.76
Percent B (%b) 0.24
BandWidth 20.36
MACD Line -16.85
MACD Signal Line -14.57
MACD Histogram -2.275
Fundamentals Value
Market Cap 53.9 Billion
Num Shares 105 Million
EPS 27.29
Price-to-Earnings (P/E) Ratio 18.84
Price-to-Sales 6.36
Price-to-Book 5.36
PEG Ratio 0.98
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 531.46
Resistance 3 (R3) 533.26 529.27 528.56
Resistance 2 (R2) 529.27 524.84 528.37 527.59
Resistance 1 (R1) 521.67 522.11 519.68 519.87 526.63
Pivot Point 517.68 517.68 516.68 516.78 517.68
Support 1 (S1) 510.08 513.25 508.08 508.27 501.51
Support 2 (S2) 506.09 510.52 505.19 500.55
Support 3 (S3) 498.49 506.09 499.58
Support 4 (S4) 496.68